102922-72-5

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-ALPHA-Z-2-AMINO-6-HYDROXYHEXANOIC ACID DICYCLOHEXYLAMINE is used as an intermediate in the synthesis of various pharmaceutical compounds, such as Lysine Norleucine (L488750). (S)-N-ALPHA-Z-2-AMINO-6-HYDROXYHEXANOIC ACID DICYCLOHEXYLAMINE is a derivative of lysine and hydroxylysine, which are essential amino acids, and is utilized for the treatment of both malignant and benign tumors.
In the synthesis process, (S)-N-ALPHA-Z-2-AMINO-6-HYDROXYHEXANOIC ACID DICYCLOHEXYLAMINE serves as a key building block, contributing to the development of therapeutic agents that target cancer cells and potentially improve patient outcomes. Its unique structure allows for the creation of novel compounds with enhanced properties, such as increased stability, selectivity, and bioavailability.
Additionally, (S)-N-ALPHA-Z-2-AMINO-6-HYDROXYHEXANOIC ACID DICYCLOHEXYLAMINE may also find applications in other industries, such as materials science, where its specific chemical properties could be harnessed for the development of new materials with tailored characteristics. However, further research and development would be required to explore these potential applications fully.

Upstream product

• 2212-75-1 N₂-[(benzyloxy)carbonyl]-L-lysine 
• 56-87-1 L-lysine 
• 657-27-2 L-Lysine hydrochloride 
• 14511-39-8 2(S)-2-amino-6-(benzylideneamino)hexanoic acid 
• 6033-32-5 (S)-2-amino-6-hydroxyhexanoic acid 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 16377-00-7 indospicine 
• 475603-50-0 ethyl (S)-2-(((benzyloxy)carbonyl)amino)-6-cyanohexanoate 
• 735271-73-5 methyl 2(S)-2-(benzyloxycarbonylamino)-7-amino-7-iminoheptanoate 
• 475603-51-1 ethyl 2(S)-2-(benzyloxycarbonylamino)-7-amino-7-iminoheptanoate 
• 475603-49-7 ethyl 2(S)-2-(benzyloxycarbonylamino)-6-tosyloxyhexanoate 
• 6033-32-5 (S)-2-amino-6-hydroxyhexanoic acid 
• 1416327-10-0 benzyl [(6S,9S,12S)-12-(hydroxymethyl)-9-(2-methylpropyl)-7,10-dioxo-1,8,11,15-tetraazabicyclo[12.2.1]heptadeca-14⁽¹⁷⁾,15-dien-6-yl]carbamate 
• 1416327-11-1 benzyl [(6S,9S,12S)-12-formyl-9-(2-methylpropyl)-7,10-dioxo-1,8,11,15-tetraazabicyclo[12.2.1]heptadeca-14⁽¹⁷⁾,15-dien-6-yl]carbamate 
• 1416327-15-5 methyl N-[(tert-butoxy)carbonyl]-L-leucyl-1-[(5S)-5-{[(benzyloxy)carbonyl]amino}-6-(tert-butoxy)-6-oxohexyl]-L-histidinate 
• 1416327-16-6 C₂₇H₃₉N₅O₇ 
• 254106-02-0 tert-butyl N-[(benzyloxy)carbonyl]-6-iodo-L-norleucinate 
• 1416327-09-7 methyl (6S,9S,12S)-6-{[(benzyloxy)carbonyl]amino}-9-(2-methylpropyl)-7,10-dioxo-1,8,11,15-tetraazabicyclo[12.2.1]heptadeca-14⁽¹⁷⁾,15-diene-12-carboxylate 
• 495401-20-2 tert-butyl (S)-2-(((benzyloxy)carbonyl)amino)-6-hydroxyhexanoate 
• 1417177-28-6 8-benzyl 1-ethyl (7S)-7-{[(benzyloxy)carbonyl]amino}-2-{[(tert-butoxy)carbonyl]amino}-2-cyanooctanedioate 

Relevant academic research and scientific papers

Selective Targeting of AF9 YEATS Domain by Cyclopeptide Inhibitors with Preorganized Conformation

YEATS domains are newly identified epigenetic "readers"of histone lysine acetylation (Kac) and crotonylation (Kcr). The malfunction of YEATS-Kac/Kcr interactions has been found to be involved in the pathogenesis of human diseases, such as cancer. These di

SYNTHESIS OF N-BENZYLOXYCARBONYL-L-α-AMINOADIPIC ACID, α-BENZYL ESTER

A new synthesis of N-benzyloxycarbonyl-L-α-aminoadipic acid, α-benzyl ester (1) from L-lysine monohydrochloride (2) is reported.

Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice

Plasmodium falciparum proteasome (Pf20S) inhibitors are active against Plasmodium at multiple stages—erythrocytic, gametocyte, liver, and gamete activation stages—indicating that selective Pf20S inhibitors possess the potential to be therapeutic, prophyla

MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS

The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity

Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders. As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer. Here, we report on the discovery of new small molecule inhibitors of LSD1 containing a propargylamine warhead, starting out from lysine containing substrate analogues. On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.

Orthogonally protected artificial amino acid as tripod ligand for automated peptide synthesis and labeling with [99mTc(OH2) 3(CO)3]+

1,2-Diamino-propionic acid (Dap) is a very strong chelator for the [ 99mTc(CO)3]+ core, yielding small and hydrophilic complexes. We prepared the lysine based Dap derivative l-Lys(Dap) in which the ε-NH2 group was replaced by the tripod through conjugation to its α-carbon. The synthetic strategy produced an orthogonally protected bifunctional chelator (BFC). The -NH2 group of the α-amino acid portion is Fmoc- and the -NH2 of Dap are Boc-protected. Fmoc-l-Lys(Dap(Boc)) was either conjugated to the N- and C-terminus of bombesin BBN(7-14) or integrated into the sequence using solid-phase peptide synthesis (SPPS). We also replaced the native lysine in a cyclic RGD peptide with l-Lys(Dap). For all peptides, quantitative labeling with the [99mTc(CO)3]+ core at a 10 μM concentration in PBS buffer (pH = 7.4) was achieved. For comparison, the rhenium homologues were prepared from [Re(OH2)3(CO) 3]+ and Lys(Dap)-BBN(7-14) or cyclo-(RGDyK(Dap)), respectively. Determination of integrin receptor binding showed low to medium nanomolar affinities for various receptor subtypes. The IC50 of cyclo-(RGDyK(Dap[Re(CO)3])) for αvβ3 is 7.1 nM as compared to 3.1 nM for nonligated RGD derivative. Biodistribution studies in M21 melanoma bearing nude mice showed reasonable α vβ3-integrin specific tumor uptake. Altogether, orthogonally protected l-Lys(Dap) represents a highly versatile building block for integration in any peptide sequence. Lys(Dap)-precursors allow high-yield 99mTc-labeling with [99mTc(OH2) 3(CO)3]+, forming small and hydrophilic complexes, which in turn leads to peptide radiopharmaceuticals with excellent in vivo characteristics.

New tripeptide-based macrocyclic calpain inhibitors formed by n-alkylation of histidine

Two new series of 15-membered macrocyclic peptidomimetics, in which the P1 and P3 residues of the peptide backbone are linked by a bridge containing a 1,4-disubstituted 1H-imidazole, are reported. The structure with an aldehyde at the C-terminus and the i

An alternative total synthesis of pentosidine

Pentosidine, a fluorescent advanced glycation endproduct that serves as a biomarker of diabetic complications, kidney dysfunction, oxidative stress, and aging and age-related diseases, was synthesized from 2,3-diaminopyridine and benzyloxycarbonyl (Cbz) p

Syntheses and biological activity of amamistatin B and analogs

(Chemical Equation Presented) Amamistatins A and B, natural products isolated from a strain of Nocardia, showed growth inhibition against three human tumor cell lines (IC50 0.24-0.56 μM). Structurally related mycobactins affect the growth of bo

Selective inhibitors of plasmepsin II of Plasmodium falciparum on the basis of pepstatin

A number of new inhibitors of plasmepsin II (PlmII) Plasmodium falciparum, which was one of the key factors of survival of malarial parasite, was synthesized. The inhibitors were analogues of pepstatin with different substitutions for the alanine residue.